홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Bromhexine

HCID 2442
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
3572-43-8
표준 SMILES
CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1
InChIKey
OJGDCBLYJGHCIH-UHFFFAOYSA-N
분자식
C14H20Br2N2
평균 분자량
376.13 g/mol
단동위원소 질량
373.99932

개요

Bromhexine is a substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive cough (i.e. a cough characterised by the production of sputum). It has a role as a mucolytic. It is an organobromine compound, a substituted aniline and a tertiary amino compound. It is a conjugate base of a bromhexine(1+).

이름 및 식별자

우선 이름
Bromhexine
IUPAC
2,4-dibromo-6-[[cyclohexyl(methyl)amino]methyl]aniline
영어명
Bromohexine
분자식
C14H20Br2N2
분자량
376.13

이름 및 동의어

bromhexine3572-43-8Benzenemethanamine, 2-amino-3,5-dibromo-N-cyclohexyl-N-methyl-BromhexinaBromhexinumFluibron2,4-dibromo-6-[[cyclohexyl(methyl)amino]methyl]aniline2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)anilineQ1J152VB1PCHEBI:770322,4-dibromo-6-{[cyclohexyl(methyl)amino]methyl}anilineDTXSID6022686
이름 더 보기
BroMhexine IMpurity EBromexineAuxitNa 274Aids001646Aids-001646BromohexineAKOS B015997AURORA KA-7546
NA274N-cyclohexyl-N-methyl-(2-amino-3,5-dibrombenzyl)amine3,5-dibromo-N(alpha)-cyclohexyl-N(alpha)-methyltoluene-alpha-2-diamineBromexinaDurElixbromhexin von ctDur ElixBC, Bromhexin

데이터베이스 식별자

CAS
3572-43-8
PubChem CID
2442
DTXSID
DTXSID6022686
ChEMBL

물성

구조 계산 물성

XLogP
4.3
극성 표면적
29.3 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
2
회전 가능 결합 수
3
무거운 원자 수
18
형식 전하
0
복잡도
256

실험 및 물리화학적 성질

Drugs · 2건

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

Solubility<1 mg/mL
Human Drugs · 2건

Breast Feeding; Lactation; Milk, Human; Expectorants

Pharmaceuticals

Melting Point232-235
Dissociation Constants8.69
Collision Cross Section167.85 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

물리화학적 성질

녹는점
238 ℃ · 238℃
끓는 점
413.8 · 413.8±40.0 °C(Predicted)
밀도
1.57 · 1.57
저장 조건
2 · 2-8°C(protect from light)
용해도
75 mg/mL · DMSO: 75 mg/mL (199.40 mM);Ethanol: 75 mg/mL (199.40 mM)
산도 계수 (pKa)
8.34 · 8.34±0.20(Predicted)
수용성
Water: Insoluble

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Warning

H400 (100%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]

P273, P391, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Regulatory Information · 3건

Chemical: Benzenemethanamine, 2-amino-3,5-dibromo-N-cyclohexyl-N-methyl-

REACH registered substance: Bromhexine (EC: 222-684-1)

Bromhexine: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Other Safety InformationIMAP assessments - Benzenemethanamine, 2-amino-3,5-dibromo-N-cyclohexyl-N-methyl-: Environment tier I assessment
Hazard Classes and CategoriesAquatic Acute 1 (100%)

독성 정보

Drug Induced Liver Injury · 4건

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Bromhexine

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

안전 데이터

독성
Approx LD50 orally in rabbits: >10 g/kg (Boyd, Sheppard)

화학 및 산업

약리 정보

ATC Code · 3건

R05CB02

R - Respiratory system

QR - Respiratory system

Protein BindingBromhexine is approximately 95% bound to plasma proteins.
PharmacodynamicsBromhexine thins airway secretions, improving breathing and discomfort associated with thick mucus in airways associated with a variety of respiratory conditions.
Mechanism of Action · 1건

Inflammation of the airways, increased mucus secretion, and altered mucociliary clearance are the hallmarks of various diseases of the respiratory tract. Mucus clearance is necessary for lung health; bromhexine aids in mucus clearance by reducing the viscosity of mucus and activating the ciliary epithelium, allowing secretions to be expelled from the respiratory tract. Recent have studies have demonstrated that bromhexine inhibits the transmembrane serine protease 2 receptor (TMPRSS2) in humans. Activation of TMPRSS2 plays an important role in viral respiratory diseases such as influenza A and Middle East Respiratory Syndrome (MERS). Inhibition of receptor activation and viral entry by bromhexine may be effective in preventing or treating various respiratory illnesses, including COVID-19. In vitro studies have suggested the action of ambroxol (a metabolite of bromhexine) on the angiogensin-converting enzyme receptor 2 (ACE2), prevents entry of the viral envelope-anchored spike glycoprotein of SARS-Cov-2 into alveolar cells or increases the secretion of surfactant, preventing viral entry.

Biological Half-LifeFollowing single oral doses ranging from 8 and 32 mg, the terminal half-life of bromhexine has been measured between 6.6 and 31.4 hours.
Metabolism/Metabolites · 1건

Bromhexine is almost completely metabolized to a variety of hydroxylated metabolites in addition to dibromanthranilic acid. Ambroxol is a known metabolite of bromhexine. In one study of human plasma, (E)-4-hydroxydemethylbromhexine (E-4-HDMB) and (E)-3-hydroxydemethylbromhexine (E-3-HDMB) were quantified as major metabolites of ambroxol, and (Z)-4-hydroxydemethylbromhexine and (Z)-3-hydroxydemethylbromhexine were quantified as minor metabolites.

관련 반응

1건
반응 기록 만들기
HRID 1506608 반응식
HRID 1506608생성물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
CHEMBL253376
ChEBI
CHEBI:77032
UNII
Q1J152VB1P
EC Number
222-684-1
Nikkaji
J8.165E
InChI
InChI=1S/C14H20Br2N2/c1-18(12-5-3-2-4-6-12)9-10-7-11(15)8-13(16)14(10)17/h7-8,12H,2-6,9,17H2,1H3
InChIKey
OJGDCBLYJGHCIH-UHFFFAOYSA-N
SMILES
C1(CN(C2CCCCC2)C)=CC(Br)=CC(Br)=C1N
HS 번호
2921590090
MeSH Pharmacological ClassificationAgents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here.
Absorption, Distribution and Excretion · 4건

After oral administration, bromhexine demonstrates linear pharmacokinetics when given in doses of 8-32 mg. Bromhexine is readily absorbed in the gastrointestinal tract at a rapid rate. This drug undergoes extensive first-pass effect in the range of 75-80%. The bioavailability is therefore reduced to approximately 22-27%.

After a dose of bromhexine was administered during a pharmacokinetic study, approximately 97% of the radiolabeled dose was detected in the urine; under 1% was detected as the parent drug.

After intravenous administration in a pharmacokinetic study, bromhexine was found to be widely distributed. Bromhexine is known to cross the blood-brain barrier; small concentrations may cross the placenta. The average volume of distribution of bromhexine was 1209 ± 206 L (19 L/kg). Lung tissue concentrations of bromhexine two hours after a dose were 1.5 to 3.2 times higher in bronchial tissues than plasma concentrations. Pulmonary parynchema concentrations were 3.4 to 5.9 times higher when compared to plasma concentrations.

The clearance of bromhexine ranges from 843-1073 mL/min, within the range of the hepatic circulation.

용도 및 제조

UsesUse (kg; approx.) in Germany (2009): >250
Use ClassificationPharmaceuticals

응용 분야

용도Expectorant; mucolytic.

상·하류 제품 정보

상류 원료

2-니트로벤질브로마이드히드라진메틸시클로헥실아민
추가 설명 · 1건

정의ChEBI: A substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive ough (i.e. a cough characterised by the production of sputum).